10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth

10x Genomics, Inc.

2023-FY EPS reported -$2.18 revenue$618,727,000

Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.
Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.
Full year 2023 net loss $255.1M, widened from $166.0M in 2022.
FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $184.0 million for the fourth quarter and $618.7 million for the full year of 2023
Net income: Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond
Guidance: initiated
Result: reported results

Exact text from the filing

10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.